ZIOPHARM Oncology, Inc. (ZIOP) announced positive preliminary overall survival, or OS, data from its randomized, controlled Phase 2 trial of palifosfamide plus doxorubicin versus doxorubicin alone, or PICASSO, in patients with unresectable or metastatic soft tissue sarcoma.
An analysis of the OS data conducted according to the statistical analysis plan, with greater than 70% of events occurring and follow-up of 33 months, showed a meaningfully positive trend favoring the palifosfamide arm. This well-controlled trial is demonstrating longer than expected survival in a difficult to treat population, the company noted.
ZIOPHARM stated that at 2-years after starting treatment, around 40% of subjects treated with palifosfamide are alive and 30% in the control arm treated with doxorubicin are alive, compared to an expected 25% based on randomized data.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.